Drugs / Ethyl Eicosapentaenoic Acid
Ethyl Eicosapentaenoic Acid
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00001146 | Oct 1999 → Aug 2002 | bipolar disorder, depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00634361 | Sep 2001 → Aug 2005 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT00419146 | Sep 2001 → Apr 2004 | schizoaffective disorder, schizophrenia, schizophreniform disorder | University Hospital, Aker | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04811404 | Mar 2021 → Jul 2022 | bipolar disorder | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethyl Eicosapentaenoic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811404 ↗ |
| Known as | EPA | “Ethyl-eicosapentaenoic acid (EPA)” NCT00419146 ↗ |
| Known as | ethyl-EPA, an omega-3 fatty acid | “ethyl-EPA, an omega-3 fatty acid” NCT00634361 ↗ |
| Route | Oral | “Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day” NCT04811404 ↗ |